These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6238441)

  • 1. Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.
    Noll G; Lämmle B; Duckert F
    Thromb Haemost; 1984 Jul; 51(3):334-7. PubMed ID: 6238441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical changes noted during intermittent administration of streptokinase.
    Verstraete M; Vermylen J; Schetz J
    Thromb Haemost; 1978 Feb; 39(1):61-8. PubMed ID: 148118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent plasminogen-streptokinase treatment of deep vein thrombosis.
    Scully MF; Lane DA; Sagar S; Thomas DP; Kakkar VV
    Thromb Haemost; 1977 Feb; 37(1):162-9. PubMed ID: 138963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic properties of the activator complexes plasmin--staphylokinase and plasmin(ogen)--streptokinase in vitro.
    Sazonova IY; Aisina RB; Muhametova LI; Varfolomeyev SD
    Biochemistry (Mosc); 1999 Jan; 64(1):66-74. PubMed ID: 9986915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
    Holvoet P; de Boer A; Verstreken M; Collen D
    Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic treatment by infusion of streptokinase-plasminogen-complex (activator): laboratory effects.
    Martin H; Auel H; Riedel C
    Behring Inst Mitt; 1986 Feb; (79):263-71. PubMed ID: 2424424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
    Leebeek FW; Kluft C; Knot EA; Los P; Cohen AF; Six AJ
    J Am Coll Cardiol; 1990 May; 15(6):1212-20. PubMed ID: 1691750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential treatment of deep leg vein thrombosis with porcine plasmin and low dose streptokinase.
    Marbet GA; Eichlisberger R; Duckert F; de Silva MA; Biland L; Widmer LK; Ritz R; Schmitt HE
    Thromb Haemost; 1982 Oct; 48(2):190-5. PubMed ID: 6217581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism.
    Dupe RJ; English PD; Smith RA; Green J
    Thromb Haemost; 1984 Apr; 51(2):248-53. PubMed ID: 6234676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
    Dupe RJ; English PD; Smith RA; Green J
    Thromb Haemost; 1981 Aug; 46(2):528-34. PubMed ID: 6458112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of SK-human plasmin, SK-dog plasmin complexes with alpha 2-antiplasmin and alpha 2-macroglobulin.
    Reddy KN; Cercek B; Lew AS; Ganz W
    Thromb Res; 1986 Mar; 41(5):671-80. PubMed ID: 2421434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of streptokinase-human plasmin complex by the plasma proteinase inhibitors alpha 2-antiplasmin and alpha 2-macroglobulin is species specific and temperature dependent.
    Gonias SL; Figler NL; Braud LL
    Blood; 1988 Nov; 72(5):1658-64. PubMed ID: 2460159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
    Collen D; Lijnen HR; Vanderschueren S
    Verh K Acad Geneeskd Belg; 1995; 57(3):183-96; discussion 196-8. PubMed ID: 7483814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis.
    Smith RA; Dupe RJ; English PD; Green J
    Thromb Haemost; 1982 Jun; 47(3):269-74. PubMed ID: 6214039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Degradation of streptokinase and the catalytic properties of the plasmin-streptokinase complex].
    Hrynenko TV; Makohonenko IeM; Iusova OI; Cederholm-Williams SA
    Ukr Biokhim Zh (1999); 2002; 74(3):50-7. PubMed ID: 12916237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.
    Edelberg JM; Pizzo SV
    Biochem J; 1992 Aug; 286 ( Pt 1)(Pt 1):79-84. PubMed ID: 1381585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of age on in vitro plasmin generation in the presence of fibrin monomer.
    Parmar N; Mitchell LG; Berry LR; Andrew M; Chan AK
    Acta Haematol; 2006; 115(3-4):141-51. PubMed ID: 16549888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side effects of thrombolytic treatment with porcine plasmin and low dose streptokinase.
    Marbet GA; Eichlisberger R; Duckert F; Ritz R; da Silva MA; Biland L; Widmer LK; Schmitt HE
    Thromb Haemost; 1982 Oct; 48(2):196-200. PubMed ID: 6217582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
    McRoyan DK; McRoyan CJ; Sauter KL; Liu PI; Daniel SJ
    Ann Clin Lab Sci; 1985; 15(2):165-70. PubMed ID: 3158265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.